Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma

Reem Karmali*, Mohamad Kassar, Parameswaran Venugopal, Jamile M. Shammo, Henry C. Fung, Robert Bayer, Teresa O'Brien, Stephanie A. Gregory

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Agricultural and Biological Sciences

Immunology and Microbiology